On August 24, 2026, the United States District Court for the Southern District of California preliminarily approved a settlement resolving a stockholder derivative action (Kanner et al. v. Biggar et al.) alleging that directors breached fiduciary duties regarding the FDA's rejection of Acadia's supplemental New Drug Application for pimavanserin. The settlement requires the adoption and maintenance of corporate governance reforms for four years and mandates payment of $1,500,000 in attorneys' fees to stockholders' counsel from an escrow account. No monetary recovery is provided to shareholders. A final approval hearing is scheduled for January 13, 2027. Acadia Pharmaceuticals Inc. operates in the biopharmaceutical industry and develops treatments for central nervous disorders.

Acadia Pharmaceuticals reported second quarter 2026 financial results, posting GAAP total revenues of $308 million, a 17% increase from the prior year period. Net income was $32 million, or $0.18 per diluted share, compared to $27 million in Q2 2025. NUPLAZID net sales reached $183 million, up 9% year-over-year, while DAYBUE net sales grew 30% to $125 million. The company raised its full-year 2026 total revenue guidance to a range of $1.24 to $1.30 billion from the previous estimate of $1.22 to $1.28 billion. Additionally, Acadia received FDA Fast Track designation for remlifanserin in Alzheimer's disease psychosis and announced that EMA CHMP adopted a positive opinion recommending marketing authorization for DAYBUE in Rett syndrome. The company operates in the pharmaceutical industry, developing and commercializing treatments for neurological and rare diseases.